Johnson & Johnson (JNJ) FCF Payout Ratio (2009 - 2026)
Johnson & Johnson (JNJ) posted FCF Payout Ratio of 0.44 for Q2 2026, down 79.3% sequentially from 2.14 in Q1 2026, and down 59.92% YoY from 1.1 in Q2 2025.
Johnson & Johnson (JNJ) FCF Payout Ratio (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported FCF Payout Ratio for 18 years, with the latest figure at 0.44 in Q2 2026.
- Quarterly FCF Payout Ratio fell 59.92% year-over-year to 0.44 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 0.57 (down 12.93% YoY) and the FY2025 annual result came in at 0.63, up 5.49% from the prior year.
- FCF Payout Ratio eased to 0.44 in Q2 2026 per JNJ's latest filing, from 2.14 in the prior quarter.
- Over five years, FCF Payout Ratio peaked at 2.14 in Q1 2026 and troughed at 0.39 in Q3 2025.
- A 5-year average of 0.88 and a median of 0.73 in 2022 frame the typical range for FCF Payout Ratio.
- The sharpest annual moves came in 2023 and 2026: FCF Payout Ratio plunged 76.86% in 2023, then jumped 141.61% in 2026.
- Over 5 years, FCF Payout Ratio stood at 0.83 in 2022, then plunged by 44.75% to 0.46 in 2023, then gained by 21.66% to 0.56 in 2024, then gained by 2.99% to 0.57 in 2025, then decreased by 22.69% to 0.44 in 2026.
- According to Business Quant data, FCF Payout Ratio over the past three periods registered 0.44, 2.14, and 0.57 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 0.44 |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 0.99 |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 0.48 |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 0.52 |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -3.54 |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 0.39 |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 0.30 |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 8.12 |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 0.44 |
| Mar 29, 2026 | 2.14 |
| Dec 28, 2025 | 0.57 |
| Sep 28, 2025 | 0.39 |
| Jun 29, 2025 | 1.10 |
| Mar 30, 2025 | 0.88 |
| Dec 29, 2024 | 0.56 |
| Sep 29, 2024 | 0.43 |
| Jun 30, 2024 | 0.64 |
| Mar 31, 2024 | 1.01 |
| Dec 31, 2023 | 0.46 |
| Oct 1, 2023 | 0.44 |
| Jul 2, 2023 | 1.01 |
| Apr 2, 2023 | 1.23 |
| Jan 1, 2023 | 1.97 |
| Apr 3, 2022 | 0.83 |
| Oct 3, 2021 | 0.37 |
| Jul 4, 2021 | 0.62 |
| Apr 4, 2021 | 0.78 |
| Jan 3, 2021 | 0.38 |